Human Placental Mesenchymal Stem Cells-Chorionic Villi

Overview

Human Placental Mesenchymal Stem Cells-Chorionic Villi is a cell model used for research applications where physiologically relevant identity and donor background support interpretation of experimental readouts. Human Mesenchymal Stem Cells derived from placenta (Placental -Chorionic Villi) within the Reproductive system.

Mesenchymal stem cells (MSC) derived from human placenta are a well-characterized population of adult stem cells. Number of researchers have shown that adult MSCs have a broad therapeutic potential due to their capability to renew and differentiate into various lineages of mature cells that produce fat, cartilage, bone, tendon, and muscle when cultured under specific permissive conditions [1] . In addition, placenta derived MSC show differentiation capacity toward both osteo-blasts and adipocytes thus serving as a great model for studying the molecular basis of differentiation [2] . These properties, in combination with their developmental plasticity, have generated tremendous interest in regenerative medicine to replace damaged tissues. These findings have spurred the development of MSC-based therapies for treating wide range of non-skeletal diseases [3] . iXCells Biotechnologies provides placental MSC isolated from different layers of human placenta, including decidua ( Cat# 10HU-170 ), chorionic villi (Cat# 10HU-171), and chorionic plate ( Cat# 10HU-172 ). Each vial contains ≥ 0.5 million cells. These cells are expanded in Mesenchymal Stem Cell Medium ( Cat# MD-0037 ) and then cryopreserved at passage 2. The human placental MSC express typical mesenchymal cell surface markers, such as CD105, CD73, and CD90 and are negative for hematopoietic markers including CD34, CD45 and endothelial cell marker CD31 [ Figure 1, 2 ]. These cells can further be differentiated into adipocytes using Adipocyte Differentiation Medium ( Cat# MD-0005 ) and into osteoblasts using Osteogenic Differentiation Medium ( Cat# MD-0006 ) [ Figure 3 and Figure 4 ]. Human placental MSC are negative for mycoplasma, bacteria, yeast, and fungi and can be expanded for no more than 3 passages in iXCells’ Mesenchymal Stem Cell Medium. Figure 1 . Top : Phase contrast images of human placental mesenchymal stem cell-Decidua (Cat# 10HU-170) taken at day 1 and day 3 post-recovery. Bottom : ICC staining using antibodies against CD73 (Green) and CD90 (Green), separately.

Key elements and design rationale

• Cell identity: Mesenchymal Stem Cells (Primary Cells)
• Source context: placenta; Placental -Chorionic Villi; Reproductive
• Donor background: Age: Adult; Gender: Female
• Biosafety level: BSL-2 (follow your institution’s biosafety program and local regulations)

Product-specific elements (such as tissue source, donor background, and cell classification) help frame how results should be interpreted across assays and experimental conditions.

Biological background

Stem and progenitor cell models are widely used to study differentiation programs, lineage commitment, and regenerative responses under controlled culture perturbations.

Across primary and specialty cell models, experimental outcomes can be influenced by donor heterogeneity, passage history, confluence, and media composition. For interpretation, it is common to validate key markers or functional phenotypes in the user’s assay context and to document culture variables consistently.

Research relevance and current trends

• Increasing use of primary and specialty cells to improve translational relevance for target biology and phenotypic screening.
• Adoption of 3D culture formats and co-culture systems to better capture tissue microenvironments and cell–cell interactions.
• Integration of functional readouts with single-cell and multi-omics profiling to connect phenotype with molecular state.

Common research applications

• Profile identity markers by flow cytometry or immunostaining in cultured cells
• Induce lineage differentiation and track marker changes over a maturation time-course
• Quantify functional responses to defined stimuli relevant to the model system
• Compare baseline phenotype across donors/conditions using gene expression profiling
• Evaluate multipotency using lineage-specific staining and gene expression panels

Interpretation typically focuses on how a perturbation (e.g., cytokine exposure, metabolic stress, genetic manipulation, or compound treatment) shifts marker profiles or functional readouts relative to an appropriate control matched for donor and culture variables.

Notes for experimental interpretation

• Donor-to-donor heterogeneity can influence baseline phenotype and treatment response; include biological replicates when feasible.
• Passage number, confluence, and media composition can shift gene expression and functional readouts; track and report these variables consistently.
• Contamination control (including routine mycoplasma monitoring) supports reproducibility in downstream assays.
• Use appropriate negative/positive controls for the readout (e.g., unstimulated controls, pathway agonists/antagonists) to contextualize observed changes.

SKU:BHC18500057

Customization & Add-ons: Can't find the cell line you need—or require a custom cell-based solution for your project? We can help you source the best match or support custom cell line services for diverse research needs, including cell line sourcing and selection (species, tissue, and disease model matching), stable cell line engineering (overexpression, knockdown, or knockout via CRISPR/Cas9, shRNA, or sgRNA), reporter gene integration (GFP, RFP, luciferase, and other fluorescent or bioluminescent constructs), genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles), inducible expression systems (Tet-On/Off and other regulatable constructs), drug resistance marker selection (puromycin, G418, hygromycin, and others), custom growth and media optimisation for specific assay requirements, scale-up production for high-throughput screening campaigns, and authentication and QC services (STR profiling, mycoplasma testing, viability assessment). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.